Zimmer Biomet Holdings, Inc.
ZBH$96.55
$-0.64 (-0.66%)-0.66%
ClosedZimmer Biomet beats Q2 estimates with non-GAAP EPS $2.07, revenue $2.2B, raises 2026 revenue growth guidance to 3.9%–4.9% and EPS outlook to $8.47–$8.59
Loading chart...
IndexN/A
Market Cap18.68B
Enterprise Value24.73B
Income$0.18B
Sales$1.91B
Employees17,000
P/E11.39
P/S2.16
P/B1.40
P/C12.09
EV/EBITDA11.15
EV/Sales12.07
EPS (ttm)8.48
EarningsN/A
Gross Margin61.62%
Oper. Margin15.31%
Profit Margin8.57%
Volume1.75M
Shs Outstand0.19B
Change-0.66%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD-3.01%
Perf Year-20.31%
Perf 3Y-29.02%
Perf 5Y-43.73%
Perf 10Y-9.32%
IPO2001-07-25
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.68B | $7.39B | $6.94B | $6.83B | $6.13B | $7.98B | $7.93B | $7.80B |
| Cost of Revenue | $2.19B | $2.08B | $2.02B | $1.96B | $1.82B | $2.25B | $2.27B | $2.13B |
| Gross Profit | $5.49B | $5.31B | $4.92B | $4.87B | $4.30B | $5.73B | $5.66B | $5.67B |
| Gross Margin | 71.46% | 71.82% | 70.90% | 71.29% | 70.23% | 71.78% | 71.36% | 72.67% |
| Operating Expenses | $4.20B | $4.03B | $4.22B | $4.01B | $4.22B | $4.59B | $5.63B | $4.87B |
| Operating Income | $1.29B | $1.28B | $696.30M | $860.30M | $83.10M | $1.14B | $33.80M | $799.30M |
| Operating Margin | 16.74% | 17.28% | 10.03% | 12.60% | 1.36% | 14.25% | 0.43% | 10.24% |
| Net Income | $903.80M | $1.02B | $231.40M | $401.60M | $-138.90M | $1.13B | $-379.20M | $1.81B |
| Net Margin | 11.77% | 13.85% | 3.33% | 5.88% | -2.27% | 14.18% | -4.78% | 23.24% |
| EPS (Basic) | $4.45 | $4.91 | $1.10 | $1.93 | $-0.67 | $5.52 | $-1.86 | $9.11 |
| EBITDA | $2.25B | $2.22B | $1.49B | $1.65B | $1.01B | $2.14B | $1.06B | $1.85B |
| Stock Option Compensation Expense | $101.00M | $99.80M | $105.00M | $76.00M | $73.80M | $84.30M | $65.50M | $53.70M |
| Price To Earnings Ratio | 23.74 | 24.80 | 115.49 | 64.01 | -222.78 | 26.32 | -54.00 | 13.03 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $21.45B | $25.40B | $26.72B | $25.71B | $30.94B | $29.78B | $20.48B | $23.63B |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $21.37B | $21.50B | $21.07B | $23.46B | $24.42B | $24.64B | $24.13B | $26.01B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.89B | $9.01B | $9.04B | $10.79B | $12.22B | $12.25B | $12.85B | $14.28B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $12.47B | $12.48B | $12.02B | $12.66B | $12.19B | $12.39B | $11.27B | $11.74B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $12.47B | $12.48B | $12.02B | $12.66B | $12.19B | $12.39B | $11.27B | $11.74B |
| Total Liabilities & Stockholders Equity | $21.37B | $21.50B | $21.07B | $23.46B | $24.42B | $24.64B | $24.13B | $26.01B |
| Book Value Per Share | $61.43 | $59.84 | $57.38 | $60.72 | $58.93 | $60.42 | $55.41 | $58.13 |
| Tangible Book Value Per Share | $-5.28 | $-5.69 | $-7.71 | $-8.56 | $-19.89 | $-21.77 | $-29.50 | $-36.09 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 4.23% | 4.76% | 1.10% | 1.71% | -0.57% | 4.59% | -1.57% | 6.97% |
| Return on Equity | 7.25% | 8.20% | 1.93% | 3.17% | -1.14% | 9.13% | -3.36% | 15.46% |
| Return on Invested Capital | 5.68% | 6.28% | 2.61% | 3.56% | 0.03% | 5.01% | 0.15% | 3.30% |
| Quick Ratio | 0.99 | 0.78 | 0.97 | 0.79 | 1.03 | 0.68 | 0.90 | 0.81 |
| Current Ratio | 1.91 | 1.61 | 1.88 | 1.41 | 1.99 | 1.37 | 1.83 | 1.49 |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $903.80M | $1.02B | $231.40M | $401.60M | $-138.90M | $1.13B | $-379.20M | $1.81B |
| Depreciation | $996.30M | $951.70M | $926.40M | $937.70M | $898.40M | $1.01B | $1.04B | $1.06B |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $1.50B | $1.58B | $1.28B | $1.50B | $1.20B | $1.59B | $1.75B | $1.58B |
| Capital Expenditures | $356.80M | $394.50M | $217.60M | $152.00M | $111.90M | $404.70M | $162.70M | $156.00M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $196.00M | $200.90M | $201.20M | $200.10M | $198.50M | $196.70M | $195.20M | $193.60M |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $868.00M | $692.20M | $126.40M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $1.14B | $1.19B | $1.07B | $1.35B | $1.09B | $1.18B | $1.58B | $1.43B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stockzacks.com Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcriptseekingalpha.com ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Marketzacks.com Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimateszacks.com Zimmer Biomet Announces Second Quarter 2026 Financial Resultsprnewswire.com Can These 3 MedTech Stocks Hit Targets This Earnings Season?zacks.com Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards?zacks.com
Show 12 more stories
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More247wallst.com Gabelli Funds LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBHdefenseworld.net ABN Amro Investment Solutions Sells 15,516 Shares of Zimmer Biomet Holdings, Inc. $ZBHdefenseworld.net Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Termzacks.com D.A. Davidson & CO. Has $2.67 Million Stake in Zimmer Biomet Holdings, Inc. $ZBHdefenseworld.net Zimmer Biomet Names Chintan Desai President of Asia Pacific Regionprnewswire.com Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Resultsprnewswire.com Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?zacks.com Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?zacks.com Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in Indiareuters.com Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Dealzacks.com ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?zacks.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Discover more
You may be interested in